Aethlon Medical Appoints Larry Cowgill, D.V.M., Ph.D., To Scientific Advisory Board.Business Editors/Health/Medical Writers LA JOLLA, Calif.--(BUSINESS WIRE)--Sept. 25, 2003 Aethlon Medical, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AEMD AEMD Automotive Electric Motor Drive (US Department of Energy program) ) announced today that Larry Cowgill, D.V.M., Ph.D., has been appointed to the Company's Science Advisory Board. Dr. Cowgill is a Professor in the Department of Medicine and Epidemiology at the School of Veterinary Medicine, University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). - Davis and has nearly 30 years of experience as a clinical instructor in small animal internal medicine, nephrology nephrology Branch of medicine dealing with kidney function and diseases. An understanding of kidney physiology is important not only in treating kidney disease but in knowing the effect of drugs, diet, and hypertension on kidney disease, and vice versa. , and hemodialysis. He currently Heads the Companion Animal Hemodialysis Units at the Veterinary Medical Teaching Hospital at UC Davis and the UC Veterinary Medical Center-San Diego. Dr. Cowgill is also Associate Dean for Southern California Clinical Programs and is Co-Director of the University of California Veterinary Medical Center-San Diego. Prior to his appointment at the University of California, he was a National Institutes of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ) Special Research Fellow at the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. School of Veterinary Medicine and at the Renal Electrolyte Section at the University of Pennsylvania School of Medicine The University of Pennsylvania's School of Medicine, presently located in the University City section of Philadelphia, Pennsylvania, was the United States's first school of medicine, founded at the College of Philadelphia, as the University was then called. , where he conducted research in basic renal physiology and clinical nephrology. Dr. Cowgill received his D.V.M. from the University of California - Davis School of Veterinary Medicine and his Ph.D. in Comparative Medical Sciences from the University of Pennsylvania, where he also completed his internship and Residency training in Small Animal Internal Medicine. He became a Diplomat of the American College of Veterinary Internal Medicine in 1977. Dr. Cowgill has published extensively in the area of veterinary nephrology and has established a Clinical Fellowship in Renal Medicine and Hemodialysis which is the first of its kind in veterinary Medicine. About Aethlon Medical Aethlon Medical is developing therapeutic devices that treat HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removed 55% of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. from human blood in three hours and in excess of 85% in twelve hours. AEMD-45 is also able to clear 90% of toxic proteins (gp-120) that deplete de·plete v. 1. To use up something, such as a nutrient. 2. To empty something out, as the body of electrolytes. immune cells in one hour. AEMD-45, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. cleared artificial kidneys (hemodialysis cartridges) to bind infectious viruses and toxic proteins from human blood before cells are infected. In January of 2003, the Company completed early stage blood studies of its HCV-Hemopurifier, which documented the ability to remove 58 percent of the Hepatitis-C virus from infected blood in two hours. For more information, visit the company's Web site at www.AethlonMedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion